Literature DB >> 31858337

Meta-analysis: diagnostic accuracy of the citrullinated peptides derived from fibrinogen and vimentin in rheumatoid arthritis.

Xue Li1, Zhenni Wang2, Han Yi1, Jun Xie3, Naishuo Zhu4,5.   

Abstract

OBJECTIVES: Anticitrullinated protein/peptide antibodies (ACPAs) have shown valuable effects in the diagnosis of rheumatoid arthritis (RA). Both fibrinogen and vimentin are significant antigens of ACPAs. This study evaluated the diagnostic performance of fibrinogen and vimentin peptides in RA.
METHODS: We searched the PubMed, Embase, and Cochrane Library databases for studies published in English until January 2019 that evaluated the utility of the peptides of both vimentin and fibrinogen. The bivariate mixed-effects model and summary receiver operating characteristic (SROC) curve were used to estimate sensitivity and specificity across studies.
RESULTS: Seven peptides from 19 studies were included. The pooled sensitivities of Fibα36-50, Fibα563-583, Fibα580-600, Fibα621-635, Fibβ36-52, Fibβ60-74, and Vim60-75 were 35%, 41%, 18%, 26%, 0.53%, 57%, and 44%, respectively. The pooled specificities of Fibα36-50, Fibα563-583, Fibα580-600, Fibα621-635, Fibβ36-52, Fibβ60-74, and Vim60-75 were 97%, 98%, 98%, 98%, 97%, 98%, and 98%, respectively. The SROC areas under the curve (AUCs) of Fibα36-50, Fibα563-583, Fibα580-600, Fibα621-635, Fibβ36-52, Fibβ60-74, and Vim60-75 were 0.92, 0.85, 0.64, 0.82, 0.91, 0.96, and 0.86, respectively.
CONCLUSION: Both fibrinogen and vimentin peptides have a high specificity but a relatively low sensitivity in diagnosing RA. The diagnostic accuracies of Fibβ60-74 and Fibβ36-52 were better than those of Vim60-75, Fibα36-50, and Fibα563-583, and all of them were better than that of Fibα621-635 and Fibα580-600.Key Points• Our study summarized the diagnostic accuracy of peptides derived from fibrinogen and vimentin and evaluated the diagnostic value of different peptides for RA patients.• Both fibrinogen and vimentin peptides have a high specificity but a relatively low sensitivity in diagnosing RA.

Entities:  

Keywords:  Anticitrullinated protein/peptide antibodies; Fibrinogen; Meta-analysis; Rheumatoid arthritis; Vimentin

Year:  2019        PMID: 31858337     DOI: 10.1007/s10067-019-04845-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  46 in total

1.  Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile.

Authors:  Karin Lundberg; Camilla Bengtsson; Nastya Kharlamova; Evan Reed; Xia Jiang; Henrik Kallberg; Iskra Pollak-Dorocic; Lena Israelsson; Christoph Kessel; Leonid Padyukov; Rikard Holmdahl; Lars Alfredsson; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2012-06-01       Impact factor: 19.103

2.  Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients.

Authors:  Omri Snir; Mary Rieck; John A Gebe; Betty B Yue; Crystal A Rawlings; Gerald Nepom; Vivianne Malmström; Jane H Buckner
Journal:  Arthritis Rheum       Date:  2011-10

3.  The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis.

Authors:  Morteza Malakoutikhah; María J Gómara; José A Gómez-Puerta; Raimon Sanmartí; Isabel Haro
Journal:  J Med Chem       Date:  2011-10-07       Impact factor: 7.446

4.  Introduction to systematic reviews and meta-analysis.

Authors:  Joanne E McKenzie; Elaine M Beller; Andrew B Forbes
Journal:  Respirology       Date:  2016-05       Impact factor: 6.424

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.

Authors:  A Jimmy Ytterberg; Vijay Joshua; Gudrun Reynisdottir; Nataliya K Tarasova; Dorothea Rutishauser; Elena Ossipova; Aase Haj Hensvold; Anders Eklund; C Magnus Sköld; Johan Grunewald; Vivianne Malmström; Per Johan Jakobsson; Johan Rönnelid; Leonid Padyukov; Roman A Zubarev; Lars Klareskog; Anca I Catrina
Journal:  Ann Rheum Dis       Date:  2014-05-09       Impact factor: 19.103

Review 7.  Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review.

Authors:  J J Luime; E M Colin; J M W Hazes; E Lubberts
Journal:  Ann Rheum Dis       Date:  2009-03-15       Impact factor: 19.103

8.  Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.

Authors:  Mikael Brink; Monika Hansson; Linda Mathsson; Per-Johan Jakobsson; Rikard Holmdahl; Göran Hallmans; Hans Stenlund; Johan Rönnelid; Lars Klareskog; Solbritt Rantapää-Dahlqvist
Journal:  Arthritis Rheum       Date:  2013-04

Review 9.  Biomarkers in Rheumatoid Arthritis, what is new?

Authors:  B I Gavrilă; C Ciofu; V Stoica
Journal:  J Med Life       Date:  2016 Apr-Jun

10.  The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.

Authors:  Maria Karolina Jonsson; Aase Haj Hensvold; Monika Hansson; Anna-Birgitte Aga; Joseph Sexton; Linda Mathsson-Alm; Martin Cornillet; Guy Serre; Siri Lillegraven; Bjørg-Tilde Svanes Fevang; Anca Irinel Catrina; Espen Andre Haavardsholm
Journal:  Arthritis Res Ther       Date:  2018-07-13       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.